[Apolipoprotein B and small, dense LDL-C]

Area of Science:

• Cardiovascular Medicine
• Clinical Chemistry
• Lipidology

Background:

• Coronary heart disease (CHD) risk is significantly influenced by lipid profiles.
• Apolipoprotein B-100 (apo B-100) and small, dense LDL-C (sdLDL-C) are established biomarkers for CHD.
• Elevated levels of these markers are associated with conditions like familial hypercholesterolemia, familial combined hyperlipidemia, diabetes mellitus, and metabolic syndrome.

Purpose of the Study:

• To evaluate the clinical utility of apo B-100 and sdLDL-C as risk markers for CHD.
• To investigate the differential diagnostic value of apo B-100 and sdLDL-C in various hyperlipidemic conditions.
• To determine if combined assessment of apo B-100 and sdLDL-C offers enhanced clinical information for CHD risk stratification.

Main Methods:

• Apo B-100 was measured using a fully automated turbidimetric immunoassay.
• SdLDL-C was quantified via an enzymatic homogeneous assay on an automated analyzer.
• Comparative analysis of apo B-100 and sdLDL-C levels was performed across different patient groups.

Main Results:

• Both apo B-100 and sdLDL-C are independently associated with increased CHD risk.
• Distinct patterns of apo B-100 and sdLDL-C elevation were observed: familial hypercholesterolemia showed higher apo B-100, while diabetes mellitus and metabolic syndrome showed higher sdLDL-C.
• Familial combined hyperlipidemia exhibited similar levels for both markers.
• Combined assessment revealed nuanced differences in marker tendencies across conditions.

Conclusions:

• Measuring both apo B-100 and sdLDL-C provides complementary information for CHD risk assessment.
• The differential elevation patterns of these markers can help elucidate the underlying cause of CHD.
• Combined analysis enhances clinical utility, potentially leading to more targeted and effective patient treatments.